NFE2L2 and cancer: Its clinical relevance in cancer biology and treatment is shown by NRF2 being dysregulated in many human cancers [21,22,23,24,25], especially where activating mutations, deletions, or gene amplifications affect NRF2/KEAP1 function to promote constitutive Nrf2 expression [15,26], with increased therapeutic resistance and poor outcomes [21,22,23,24,25].